SUBTROCHANTERIC FEMORAL FRACTURES IN PATIENTS ON LONG-TERM ALENDRONATE THERAPY: IMAGING FEATURES
SARAH SHOCK CHAN, ZEHAVA SADKA ROSENBERG, KEITH CHAN, CRAIG CAPECI

Background
• Osteoporosis an epidemic
– Affects 10 million Americans
– > 1.5 million osteoporosis related fxs annually
– $18 billion/ year - estimated national direct care expenditures for osteoporotic fx
• Biphosphonates = 1st line of Rx for osteoporosis
• Fosamax (alendronate sodium) FDA approved in 1999, most commonly used
• Fosamax increases bone mineral density and reduces risk of fractures in women with osteoporosis